NO BUFFETS –
Feb. 3, 2025 – The study explores the subjective experiences of individuals with binge eating disorder and prescribed lisdexamfetamine. Although many taking the medication reported reduced binge episodes and improved appetite control, others experienced significant side effects and inconsistent efficacy results.Lisdexamfetamine, marketed as Vyvanse, first received approval from the Food and Drug Administration for the treatment of ADHD, “but its ability…to also reduce the frequency of binge eating episodes led to its approval for binge eating disorder,” said Morgan James, assistant professor of psychiatry, member of the Rutgers Addiction Research Center at the Brain Health Institute, and senior author of the study. It is now the only approved medication for moderate to severe binge eating disorder in adult patients.
The study, published in Psychiatry Research Communications, explores the subjective experiences of individuals with binge eating disorder and prescribed lisdexamfetamine. Although many taking the medication reported reduced binge episodes and improved appetite control, others experienced significant side effects and inconsistent efficacy results.
